We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
As the USTR’s Special 301 Review for 2021 starts, calls for the WTO to declare an IPR waiver on all COVID-19 related medical products will pick up pace. It’s time to find middle ground.